跨国药企财报大PK:辉瑞重回第一,中国区业绩哪家强?

经济观察报
16 Feb

2024年的前十名“玩家”有了变化,葛兰素史克掉出了榜单,新入局的是礼来。前者的带状疱疹疫苗增长乏力,后者的减肥神药势头正猛。   2月以来,跨国药企密集公布2024年财报。经济观察报统计,截至2月13日,2024年全球制药企业TOP50榜单中前10名的药企都公布了2024年业绩。从业绩表现看,重新洗牌后的格局是“几家欢喜几家愁”。   辉瑞以636.27亿美元重新回到制药业务的第一把交椅,其肿瘤...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10